| Before | After |
|---|
| 1 |
<clinical_study>
<study_id>
<org_full_name>
|
<clinical_study>
<study_id>
<org_full_name>
|
| 2 |
Aeras Global TB Vaccine Foundation
|
Aeras
|
| 3 |
![[-]](/archive/collapse.gif "Hide most of the text in this chunk of XML") ![[+]](/archive/expand.gif "Show the hidden text in this chunk of XML") </org_full_name>
<org_study_id>
C-029-402
</org_study_id>
<nct_id>
NCT01198366
</nct_id>
</study_id>
<is_fda_regulated>
No
</is_fda_regulated>
<brief_title>
<textblock>
|
</org_full_name>
<org_study_id>
C-029-402
</org_study_id>
<nct_id>
NCT01198366
</nct_id>
</study_id>
<is_fda_regulated>
No
</is_fda_regulated>
<brief_title>
<textblock>
|
| 4 |
Study of Aeras 402 in Healthy Infants
|
Study of AERAS-402 in Healthy Infants
|
| 5 |
</textblock>
</brief_title>
<official_title>
<textblock>
|
</textblock>
</brief_title>
<official_title>
<textblock>
|
| 6 |
A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter, Proof-of-concept Study to Evaluate the Safety and Efficacy of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis
|
A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis
|
| 7 |
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
|
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
|
| 8 |
Aeras Global TB Vaccine Foundation
|
Aeras
|
| 9 |
</agency>
</lead_sponsor>
<sponsor>
<agency>
European and Developing Countries Clinical Trials Partnership (EDCTP)
</agency>
</sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
Kenya: Pharmacy and Poisons Board
</regulatory_authority>
<regulatory_authority>
South Africa: Medicines Control Council
</regulatory_authority>
<regulatory_authority>
Mozambique: Ministry of Health (MISAU)
</regulatory_authority>
<has_dmc>
Yes
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
AERAS-402 will be given to infants of at least 16 weeks of age who have already been vaccinated with BCG to determine if AERAS-402 will increase protection of infants to tuberculosis.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
The only currently available tuberculosis vaccine, bacillus Calmette-Guérin (BCG), is estimated to reduce the risk of tuberculosis (TB) in children by up to 70-80%, but protection is incomplete. Efforts to increase TB protection in children include new vaccines for primary immunizations as well as combinations of vaccines given as primary and boosting vaccinations. AERAS 402 presents Mycobacterium tuberculosis (Mtb) antigens in the setting of a new, live, replication-deficient adenovirus vaccine that may increase T cell-mediated immunity and thus protection from tuberculosis. AERAS-402 appears safe and immunogenic in adults. Since BCG-vaccinated infants are the population for which AERAS-402 might be indicated, AERAS-402 will be administered to infants of at least 16 weeks of age who have already been vaccinated with BCG. This is the first Phase II study of AERAS-402 in infants.
</textblock>
</detailed_descr>
<status_block>
<status>
|
</agency>
</lead_sponsor>
<sponsor>
<agency>
European and Developing Countries Clinical Trials Partnership (EDCTP)
</agency>
</sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
Kenya: Pharmacy and Poisons Board
</regulatory_authority>
<regulatory_authority>
South Africa: Medicines Control Council
</regulatory_authority>
<regulatory_authority>
Mozambique: Ministry of Health (MISAU)
</regulatory_authority>
<has_dmc>
Yes
</has_dmc>
</oversight_info>
<brief_summary>
<textblock>
AERAS-402 will be given to infants of at least 16 weeks of age who have already been vaccinated with BCG to determine if AERAS-402 will increase protection of infants to tuberculosis.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
The only currently available tuberculosis vaccine, bacillus Calmette-Guérin (BCG), is estimated to reduce the risk of tuberculosis (TB) in children by up to 70-80%, but protection is incomplete. Efforts to increase TB protection in children include new vaccines for primary immunizations as well as combinations of vaccines given as primary and boosting vaccinations. AERAS 402 presents Mycobacterium tuberculosis (Mtb) antigens in the setting of a new, live, replication-deficient adenovirus vaccine that may increase T cell-mediated immunity and thus protection from tuberculosis. AERAS-402 appears safe and immunogenic in adults. Since BCG-vaccinated infants are the population for which AERAS-402 might be indicated, AERAS-402 will be administered to infants of at least 16 weeks of age who have already been vaccinated with BCG. This is the first Phase II study of AERAS-402 in infants.
</textblock>
</detailed_descr>
<status_block>
<status>
|
| 10 |
Recruiting
|
Active, not recruiting
|
| 11 |
</status>
<date>
|
</status>
<date>
|
| 12 |
2012-01
|
2012-11
|
| 13 |
</date>
</status_block>
<start_date>
<date>
2010-09
</date>
</start_date>
|
</date>
</status_block>
<start_date>
<date>
2010-09
</date>
</start_date>
|
| 14 |
|
<last_follow_up_date
type="Anticipated"
>
<date>
2014-03
</date>
</last_follow_up_date>
|
| 15 |
<primary_compl_date
<date>
|
<primary_compl_date
<date>
|
| 16 |
2014-12
|
2013-12
|
| 17 |
</date>
</primary_compl_date>
<phase_block>
<phase>
Phase 1
</phase>
<phase>
Phase 2
</phase>
</phase_block>
<study_type>
Interventional
</study_type>
<design>
Prevention
</design>
<design>
Randomized
</design>
<design>
Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
</design>
<design>
Parallel Assignment
</design>
<design>
|
</date>
</primary_compl_date>
<phase_block>
<phase>
Phase 1
</phase>
<phase>
Phase 2
</phase>
</phase_block>
<study_type>
Interventional
</study_type>
<design>
Prevention
</design>
<design>
Randomized
</design>
<design>
Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
</design>
<design>
Parallel Assignment
</design>
<design>
|
| 18 |
Safety/Efficacy Study
|
Safety Study
|
| 19 |
</design>
<number_of_arms>
|
</design>
<number_of_arms>
|
| 20 |
8
|
5
|
| 21 |
</number_of_arms>
<primary_outcome>
<measure>
Adverse Events collected per subject
</measure>
<time_frame>
6 to 24 months post vaccination
</time_frame>
<description>
<textblock>
AEs are recorded for 28 days post vaccination
SAEs are recorded for the entire study period to assess the safety profile
</textblock>
</description>
<safety_issue>
Yes
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
Number of cases of TB are collected in the subjects entered in the study
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the efficacy of AERAS-402 in the prevention of TB in infants based on TB case definition endpoint #1 as described in the protocol.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
Percentage of cells expressing various cytokines will be measured in all subjects
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the immunogenicity of AERAS-402 compared to controls, flow cytometric intracellular cytokine staining (ICS) of CD4 and CD8 T cells producing one, two or three cytokines (IFN-γ, TNF-α, and/or IL-2) simultaneously after stimulation with a peptide pool of mycobacterial peptides.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
Number of subjects that have positive QuantiFERON tests after vaccination
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the proportion of on-study QuantiFERON conversions in infants that received AERAS-402 compared to controls.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
Number of subjects with probable TB
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the efficacy of AERAS-402 in the prevention of TB in infants based on TB case definition endpoints #2 and #3 as specified in the protocol.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</secondary_outcome>
<enrollment
|
</number_of_arms>
<primary_outcome>
<measure>
Adverse Events collected per subject
</measure>
<time_frame>
6 to 24 months post vaccination
</time_frame>
<description>
<textblock>
AEs are recorded for 28 days post vaccination
SAEs are recorded for the entire study period to assess the safety profile
</textblock>
</description>
<safety_issue>
Yes
</safety_issue>
</primary_outcome>
<primary_outcome>
<measure>
Number of cases of TB are collected in the subjects entered in the study
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the efficacy of AERAS-402 in the prevention of TB in infants based on TB case definition endpoint #1 as described in the protocol.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
Percentage of cells expressing various cytokines will be measured in all subjects
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the immunogenicity of AERAS-402 compared to controls, flow cytometric intracellular cytokine staining (ICS) of CD4 and CD8 T cells producing one, two or three cytokines (IFN-γ, TNF-α, and/or IL-2) simultaneously after stimulation with a peptide pool of mycobacterial peptides.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
Number of subjects that have positive QuantiFERON tests after vaccination
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the proportion of on-study QuantiFERON conversions in infants that received AERAS-402 compared to controls.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
Number of subjects with probable TB
</measure>
<time_frame>
24 months post vaccination
</time_frame>
<description>
<textblock>
To evaluate the efficacy of AERAS-402 in the prevention of TB in infants based on TB case definition endpoints #2 and #3 as specified in the protocol.
</textblock>
</description>
<safety_issue>
No
</safety_issue>
</secondary_outcome>
<enrollment
|
| 22 |
type="Anticipated"
|
type="Actual"
|
| 23 |
>
|
>
|
| 24 |
4096
|
487
|
| 25 |
</enrollment>
<condition>
Tuberculosis
</condition>
<arm_group>
<arm_group_label>
Group One - Dose Finding - Low Dose
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects enrolled in Study Group 1 will be randomized in a ratio of 3:1 to receive two doses of AERAS-402 at the lowest dose level or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 2 - Dose Finding - Middle dose -
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects enrolled in Study Group 2 will be randomized in a ratio of 3:1 to receive two doses of AERAS-402 at the middle dose level or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 3 - Dose Finding - High Dose
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects enrolled in Study Group 3 will be randomized in a ratio of 3:1 to receive two doses of AERAS-402 at the highest dose level or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 5 - Safety Cohort
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
|
</enrollment>
<condition>
Tuberculosis
</condition>
<arm_group>
<arm_group_label>
Group One - Dose Finding - Low Dose
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects enrolled in Study Group 1 will be randomized in a ratio of 3:1 to receive two doses of AERAS-402 at the lowest dose level or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 2 - Dose Finding - Middle dose -
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects enrolled in Study Group 2 will be randomized in a ratio of 3:1 to receive two doses of AERAS-402 at the middle dose level or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 3 - Dose Finding - High Dose
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects enrolled in Study Group 3 will be randomized in a ratio of 3:1 to receive two doses of AERAS-402 at the highest dose level or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 5 - Safety Cohort
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
|
| 26 |
Subjects will receive two doses of AERAS-402 at the selected dose level or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 6 - ICS
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects will receive two doses of AERAS-402 at the selected dose level or placebo, once on Study Day 0 and again on Study Day 28. Subjects will have additional blood collected for the determination of immunogenicity.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 7 - Whole Blood Assay
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects will receive two doses of AERAS-402 at the selected dose level or placebo, once on Study Day 0 and again on Study Day 28. Subjects will have additional blood collected for the determination of immunogenicity.
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 8 - Correlates of Protection
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
Subjects will receive two doses of AERAS-402 at the selected dose level or placebo, once on Study Day 0 and again on Study Day 28. Subjects will have additional blood collected for the determination of potential correlates of protection.
|
|
| 27 |
|
Subjects will receive three doses of AERAS-402 at the selected dose level or placebo, once on Study Day 0, again on Study Day 28, and again on Study Day 280.
|
| 28 |
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 4 - Dose Finding Group 2
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
These additional 96 subjects will be randomized (1:1:1:1) in a parallel design to receive two doses of either AERAS-402 (1.5 x 1010, 3.0 x 1010, or 1.0 x 1011 vp) or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
Biological/Vaccine
</intervent_type>
<primary_name>
AERAS-402
</primary_name>
<description>
<textblock>
Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens
</textblock>
</description>
<arm_group_label>
Group One - Dose Finding - Low Dose
</arm_group_label>
<arm_group_label>
Group 2 - Dose Finding - Middle dose -
</arm_group_label>
<arm_group_label>
Group 3 - Dose Finding - High Dose
</arm_group_label>
<arm_group_label>
Group 5 - Safety Cohort
</arm_group_label>
<arm_group_label>
|
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
Group 4 - Dose Finding Group 2
</arm_group_label>
<arm_type>
Experimental
</arm_type>
<description>
<textblock>
These additional 96 subjects will be randomized (1:1:1:1) in a parallel design to receive two doses of either AERAS-402 (1.5 x 1010, 3.0 x 1010, or 1.0 x 1011 vp) or placebo, once on Study Day 0 and again on Study Day 28.
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
Biological/Vaccine
</intervent_type>
<primary_name>
AERAS-402
</primary_name>
<description>
<textblock>
Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis antigens
</textblock>
</description>
<arm_group_label>
Group One - Dose Finding - Low Dose
</arm_group_label>
<arm_group_label>
Group 2 - Dose Finding - Middle dose -
</arm_group_label>
<arm_group_label>
Group 3 - Dose Finding - High Dose
</arm_group_label>
<arm_group_label>
Group 5 - Safety Cohort
</arm_group_label>
<arm_group_label>
|
| 29 |
Group 6 - ICS
</arm_group_label>
<arm_group_label>
Group 7 - Whole Blood Assay
</arm_group_label>
<arm_group_label>
Group 8 - Correlates of Protection
</arm_group_label>
<arm_group_label>
|
|
| 30 |
Group 4 - Dose Finding Group 2
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
Inclusion Criteria:
1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on Study Day 0
3. Has general good health, confirmed by medical history and physical examination
4. Is up to date on all EPI immunizations for his/her age with a minimum of 14 days between the last EPI vaccination and administration of study vaccine on Study Day 0
5. Has ability to complete follow-up period of 728 days as required by the protocol
6. Parent/legal guardian is able and willing to stay in contact with the study site for the duration of the study and to provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
7. Has completed simultaneous enrollment in Aeras Vaccine Development Registry protocol
8. Had BCG vaccination ≥ 3 months prior to randomization documented by medical card
Exclusion Criteria:
1. Acute illness, evidence of any significant active infection or temperature >=37.5°C on the day of randomization
2. Used immunosuppressive medication within 45 days before entry into the study (inhaled and topical corticosteroids are permitted)
3. Received immunoglobulin or blood products within 45 days before entry into the study
4. Ever received any investigational drug therapy or investigational vaccine
5. History or laboratory evidence of individual immunodeficiency virus (HIV-1) infection
6. History of allergic disease or reactions to any component of the study vaccine
7. Previous medical history that may compromise the safety of the participant in the study
8. Evidence of a new acute illness that may compromise the safety of the participant in the study
9. Inability to discontinue daily medications during the study
10. History or evidence of any systemic disease on physical examination or any acute or chronic illness that may interfere with the evaluation of the safety or immunogenicity of the vaccine, e.g., including masses between the leg and abdomen (e.g., inguinal hernia or lymphadenopathy)
11. History or evidence of active tuberculosis
12. A positive QuantiFERON®-TB Gold In-Tube test
13. A household contact with active TB disease
</textblock>
</criteria>
<healthy_volunteers>
Yes
</healthy_volunteers>
<gender>
Both
</gender>
<minimum_age>
112 Days
</minimum_age>
<maximum_age>
182 Days
</maximum_age>
</eligibility>
<investigator>
<role>
Study Director
</role>
<name>
Robert Walker
</name>
<affiliation>
<agency>
Aeras Global TB Vaccine Foundation
</agency>
</affiliation>
</investigator>
<contact>
<name>
Videlis Nduba, MD, MPH
</name>
<phone>
254-724-522-474
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
KEMRI/CDC Research and Public Heath Collaboration
</name>
<address>
<city>
Kisumu
</city>
<state>
</state>
<zip>
40100
</zip>
<country>
Kenya
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Grace Kaguthi
</name>
<phone>
254 729 489 743
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Videlis Nduba, MD, MPH
</name>
</contact>
</location>
<location>
<facility>
<name>
Siaya District Hospital
</name>
<address>
<city>
Siaya
</city>
<state>
</state>
<zip>
</zip>
<country>
Kenya
</country>
</address>
</facility>
<status>
Active, not recruiting
</status>
<contact>
<name>
Grace Kaguthi, MD
</name>
<phone>
254-729-489-743
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Videlis Nduba, MD, MPH
</name>
</contact>
</location>
<location>
<facility>
<name>
Boro Heath Center
</name>
<address>
<city>
Boro
</city>
<state>
</state>
<zip>
</zip>
<country>
Kenya
</country>
</address>
</facility>
<status>
Active, not recruiting
</status>
<contact>
<name>
Grace Kaguthi, MD
</name>
<phone>
254-729-489-743
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Videlis Nduba, MD, MPH
</name>
</contact>
</location>
<location>
<facility>
<name>
CISM: Centro de Investigacao em Saude de Manhica
</name>
<address>
<city>
Manhica
</city>
<state>
</state>
<zip>
1929
</zip>
<country>
Mozambique
</country>
</address>
</facility>
<status>
Active, not recruiting
</status>
<contact>
<name>
Sofia Mandjate
</name>
<phone>
00258 82 4793161
</phone>
<phone_ext>
</phone_ext>
<email>
Sofia.Mandjate@manhica.net
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Jahit Sacarlal, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
SATVI: Worcester
</name>
<address>
<city>
Worcester
</city>
<state>
</state>
<zip>
6850
</zip>
<country>
South Africa
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Michele Tameris, MD
</name>
<phone>
27 23 346 5400
</phone>
<phone_ext>
</phone_ext>
<email>
michele.tameris@uct.ac.za
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Michele Tameris, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
Univeristy of Cape Town
</name>
<address>
<city>
Cape Town
</city>
<state>
</state>
<zip>
7925
</zip>
<country>
South Africa
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Hassan Mahomed, MD
</name>
<phone>
27 21 406 6697
</phone>
<phone_ext>
</phone_ext>
<email>
hassan.mahomed@uct.ac.za
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Hassan Mahomed, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
Perinatal HIV Research Unit (PHRU) Chris Hani Baragwanath Hospital
</name>
<address>
<city>
Soweto
</city>
<state>
</state>
<zip>
1864
</zip>
<country>
South Africa
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Tebogo Magopane
</name>
<phone>
27 11 989 9876
</phone>
<phone_ext>
</phone_ext>
<email>
magopanet@phru.co.za
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Glenda Gray, MD
</name>
</contact>
</location>
<keyword>
Tuberculosis
</keyword>
<keyword>
Vaccine
</keyword>
<keyword>
Immunogenicity
</keyword>
<keyword>
Prevention of Tuberculosis
</keyword>
<initial_release_date>
2010-09-07
</initial_release_date>
<last_release_date>
|
Group 4 - Dose Finding Group 2
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
Inclusion Criteria:
1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on Study Day 0
3. Has general good health, confirmed by medical history and physical examination
4. Is up to date on all EPI immunizations for his/her age with a minimum of 14 days between the last EPI vaccination and administration of study vaccine on Study Day 0
5. Has ability to complete follow-up period of 728 days as required by the protocol
6. Parent/legal guardian is able and willing to stay in contact with the study site for the duration of the study and to provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
7. Has completed simultaneous enrollment in Aeras Vaccine Development Registry protocol
8. Had BCG vaccination ≥ 3 months prior to randomization documented by medical card
Exclusion Criteria:
1. Acute illness, evidence of any significant active infection or temperature >=37.5°C on the day of randomization
2. Used immunosuppressive medication within 45 days before entry into the study (inhaled and topical corticosteroids are permitted)
3. Received immunoglobulin or blood products within 45 days before entry into the study
4. Ever received any investigational drug therapy or investigational vaccine
5. History or laboratory evidence of individual immunodeficiency virus (HIV-1) infection
6. History of allergic disease or reactions to any component of the study vaccine
7. Previous medical history that may compromise the safety of the participant in the study
8. Evidence of a new acute illness that may compromise the safety of the participant in the study
9. Inability to discontinue daily medications during the study
10. History or evidence of any systemic disease on physical examination or any acute or chronic illness that may interfere with the evaluation of the safety or immunogenicity of the vaccine, e.g., including masses between the leg and abdomen (e.g., inguinal hernia or lymphadenopathy)
11. History or evidence of active tuberculosis
12. A positive QuantiFERON®-TB Gold In-Tube test
13. A household contact with active TB disease
</textblock>
</criteria>
<healthy_volunteers>
Yes
</healthy_volunteers>
<gender>
Both
</gender>
<minimum_age>
112 Days
</minimum_age>
<maximum_age>
182 Days
</maximum_age>
</eligibility>
<investigator>
<role>
Study Director
</role>
<name>
Robert Walker
</name>
<affiliation>
<agency>
Aeras Global TB Vaccine Foundation
</agency>
</affiliation>
</investigator>
<contact>
<name>
Videlis Nduba, MD, MPH
</name>
<phone>
254-724-522-474
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
KEMRI/CDC Research and Public Heath Collaboration
</name>
<address>
<city>
Kisumu
</city>
<state>
</state>
<zip>
40100
</zip>
<country>
Kenya
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Grace Kaguthi
</name>
<phone>
254 729 489 743
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Videlis Nduba, MD, MPH
</name>
</contact>
</location>
<location>
<facility>
<name>
Siaya District Hospital
</name>
<address>
<city>
Siaya
</city>
<state>
</state>
<zip>
</zip>
<country>
Kenya
</country>
</address>
</facility>
<status>
Active, not recruiting
</status>
<contact>
<name>
Grace Kaguthi, MD
</name>
<phone>
254-729-489-743
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Videlis Nduba, MD, MPH
</name>
</contact>
</location>
<location>
<facility>
<name>
Boro Heath Center
</name>
<address>
<city>
Boro
</city>
<state>
</state>
<zip>
</zip>
<country>
Kenya
</country>
</address>
</facility>
<status>
Active, not recruiting
</status>
<contact>
<name>
Grace Kaguthi, MD
</name>
<phone>
254-729-489-743
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Videlis Nduba, MD, MPH
</name>
</contact>
</location>
<location>
<facility>
<name>
CISM: Centro de Investigacao em Saude de Manhica
</name>
<address>
<city>
Manhica
</city>
<state>
</state>
<zip>
1929
</zip>
<country>
Mozambique
</country>
</address>
</facility>
<status>
Active, not recruiting
</status>
<contact>
<name>
Sofia Mandjate
</name>
<phone>
00258 82 4793161
</phone>
<phone_ext>
</phone_ext>
<email>
Sofia.Mandjate@manhica.net
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Jahit Sacarlal, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
SATVI: Worcester
</name>
<address>
<city>
Worcester
</city>
<state>
</state>
<zip>
6850
</zip>
<country>
South Africa
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Michele Tameris, MD
</name>
<phone>
27 23 346 5400
</phone>
<phone_ext>
</phone_ext>
<email>
michele.tameris@uct.ac.za
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Michele Tameris, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
Univeristy of Cape Town
</name>
<address>
<city>
Cape Town
</city>
<state>
</state>
<zip>
7925
</zip>
<country>
South Africa
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Hassan Mahomed, MD
</name>
<phone>
27 21 406 6697
</phone>
<phone_ext>
</phone_ext>
<email>
hassan.mahomed@uct.ac.za
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Hassan Mahomed, MD
</name>
</contact>
</location>
<location>
<facility>
<name>
Perinatal HIV Research Unit (PHRU) Chris Hani Baragwanath Hospital
</name>
<address>
<city>
Soweto
</city>
<state>
</state>
<zip>
1864
</zip>
<country>
South Africa
</country>
</address>
</facility>
<status>
Recruiting
</status>
<contact>
<name>
Tebogo Magopane
</name>
<phone>
27 11 989 9876
</phone>
<phone_ext>
</phone_ext>
<email>
magopanet@phru.co.za
</email>
</contact>
<contact>
<role>
Principal Investigator
</role>
<name>
Glenda Gray, MD
</name>
</contact>
</location>
<keyword>
Tuberculosis
</keyword>
<keyword>
Vaccine
</keyword>
<keyword>
Immunogenicity
</keyword>
<keyword>
Prevention of Tuberculosis
</keyword>
<initial_release_date>
2010-09-07
</initial_release_date>
<last_release_date>
|
| 31 |
2012-01-17
|
2012-11-12
|
| 32 |
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
|
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
|
